ReNeuron Group plc - Analyst Conference Call
ReNeuron Group plc
("ReNeuron" or the "Company")
Analyst Conference Call
ReNeuron Group plc (AIM: RENE.L), a
Analysts who require dial-in details, please contact Buchanan at email@example.com.
A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of
The recorded webcast will also be made available at the investor centre of ReNeuron's website, http://www.reneuron.com/investors/investor-centre/.
+44 (0) 20 3819 8400
| || |
| || |
+44 (0) 20 7466 5000
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
+44 (0) 20 7710 7600
| || |
N+1 Singer (Joint Broker)
+44 (0) 20 7496 3000
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Quick facts: ReNeuron Group PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE